Geneos Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-210
Closed -$26.4K 2935
2025
Q2
$26.4K Sell
210
-341
-62% -$39.1K ﹤0.01% 1898
2025
Q1
$60.9K Buy
551
+457
+486% +$57.9K ﹤0.01% 1815
2024
Q4
$12.8K Hold
94
﹤0.01% 1942
2024
Q3
$10.8K Buy
+94
New +$12.9K ﹤0.01% 1813
2024
Q2
Sell
-7
Closed -$965 2143
2024
Q1
$965 Buy
+7
New +$956 ﹤0.01% 2027
2021
Q2
Sell
-11
Closed -$1K 3022
2021
Q1
$1K Buy
+11
New +$1.15K ﹤0.01% 3041
2020
Q4
Sell
-50
Closed -$4K 2962
2020
Q3
$4K Sell
50
-250
-83% -$28.9K ﹤0.01% 2266
2020
Q2
$39K Sell
300
-190
-39% -$21K ﹤0.01% 1327
2020
Q1
$43K Hold
490
﹤0.01% 1185
2019
Q4
$53K Buy
+490
New +$51.3K ﹤0.01% 1220

Other funds holding NBIX

Geneos Wealth Management's NBIX Position: Q3 2025 in Review

Geneos Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 210 shares — an estimated $26.4K sold.

Geneos Wealth Management first reported a position in NBIX in Q4 2019 and held it in 10 quarters. The position peaked at $60.9K in Q1 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Geneos Wealth Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 210 Neurocrine Biosciences shares in Q3 2025, an estimated $26.4K.
  • Geneos Wealth Management first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 10 quarters.
  • Geneos Wealth Management's Neurocrine Biosciences position peaked at $60.9K in Q1 2025.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.